Delving into the Latest Updates on Porcine Fibrin (Guangzhou Baitejing Pharmaceutical Technology) with Synapse

Overview

Basic Info

Drug Type

Blood components

Synonyms

DBT, Porcine Fibrin Sealant Patch

Target

fibrin

Action

modulators

Mechanism

fibrin modulators(Fibrin modulators)

Therapeutic Areas

Other Diseases

Active Indication

Postoperative Hemorrhage

Inactive Indication-

Originator Organization

Guangzhou Baitejing Pharmaceutical Technology Co., Ltd.

Guangzhou Zhongwei Biotechnology Co., Ltd.

Active Organization

Guangzhou Baitejing Pharmaceutical Technology Co., Ltd.

Guangzhou Zhongwei Biotechnology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

A composite gel mimicking duck blood tofu (DBT) was developed using soy protein isolate (SPI) and hemoglobin (Hb), cross-linked by transglutaminase (TGase). The effects of SPI and TGase concentrations on gel microstructure, texture, water-holding capacity, and thermal stability were evaluated. FTIR and DSC analyses revealed that the incorporation of SPI promoted the formation of β-sheet structures in Hb and improved its thermal stability. SEM revealed denser gel networks with increased SPI or TGase. Hb addition improved gel color, with 200 mg Hb yielding the closest match to DBT. Simulated cooking tests indicated that short heating preserved texture, while prolonged heating weakened it. Double-blind sensory tests confirmed a close resemblance to DBT in appearance, flavor, and acceptability. This work demonstrates a novel approach to constructing plant-animal composite protein gels with improved structural and sensory properties, providing a promising strategy for developing high-fidelity meat analogs.

01 Mar 2026·Journal of Medical Radiation Sciences

An Analysis of Acquisition Dose in Male Mammography

Article

Author: Ng, Zechary ; Carrion, Daniel ; Badawy, Mohamed K. ; Masterson, Maeve

ABSTRACT:

Introduction:

Although primarily used for female patients, mammography is a valuable tool for detecting male breast abnormalities, providing detailed images of breast tissue. Due to the low incidence of male breast imaging, limited male‐specific studies exist on radiation exposure. This study measured the acquisition radiation dose of male patients undergoing full‐field digital mammography (FFDM) and digital breast tomosynthesis (DBT) at an Australian tertiary hospital and compared these values with published cohorts. The goal was to determine whether differences in breast anatomy between sexes influenced radiation dose levels.

Methods:

A retrospective analysis of 266 male breast imaging acquisitions (66 patients, 78 procedures) across two hospital sites between February 2019 and April 2024 was performed. Both FFDM ( n = 164) and DBT ( n = 102) were assessed. Radiation dose metrics, including entrance surface air kerma (ESAK) and glandular dose (GD), were extracted from DICOM headers using a Python script. Data was anonymised and analysed with descriptive statistics, Shapiro–Wilk, Mann–Whitney U , and Pearson correlation to compare modalities and explore associations between patient and technical factors.

Results:

Median participant age was 65 years; median breast thickness 51 mm. Median FFDM variables: 28 kVp, 128 mAs, 570 ms exposure time, 2.7 mGy ESAK, 0.83 mGy GD. For DBT: 29 kVp, 100 mAs, 975 ms exposure time, 4.7 mGy ESAK, 1.34 mGy GD. Shapiro–Wilk ( p < 0.001) confirmed non‐normal distributions. DBT doses were significantly higher than FFDM (Mann–Whitney U , p < 0.001). FFDM GD values were lower than both male and female cohorts reported previously. Breast thickness correlated strongly with FFDM ESAK (Pearson r = 0.72, p < 0.001).

Conclusions:

This study quantified ESAK and GD in male FFDM and DBT patients and compared these values with published female cohorts. Male doses were consistently lower, likely from reduced breast thickness and density. This study successfully measured acquisition dose in male mammography patients, identifying differences by sex and highlighting breast anatomy's influence.

01 Feb 2026·VALUE IN HEALTH

Long-Term Outcomes and Cost-Effectiveness of Artificial Intelligence for Breast Cancer Screening: A Modeling Study

Article

Author: Kunst, Natalia ; Richman, Ilana B ; Andersen, Matthew

OBJECTIVES:

Artificial intelligence (AI)-assisted breast cancer screening may improve diagnostic accuracy; however, the long-term health outcomes and cost-effectiveness of AI-assisted screening is unknown. We estimated benefits, harms, and cost-effectiveness of incorporating an AI product, Saige-Dx, into standard screening with digital breast tomosynthesis (DBT).

METHODS:

We developed a microsimulation model using nationally representative data from Surveillance, Epidemiology, and End Results, the Breast Cancer Surveillance Consortium, and published data on AI performance. The model compared biennial screening for women aged 40 to 74 using DBT to DBT plus AI. We estimated false-positive and false-negative screens, breast cancer cases by stage, and breast cancer deaths per 1000 women screened over a lifetime. We also estimated quality-adjusted life-years (QALYs), costs, and the incremental cost-effectiveness ratio.

RESULTS:

In a cohort of 1000 women screened from ages 40 to 74, AI-assisted screening reduced false-negative screens by 2.1 and false positives by 49 resulting in 0.33 fewer advanced breast cancer cases (regional or metastatic cancer) at diagnosis and 0.13 fewer breast cancer deaths compared with DBT alone. Screening with AI resulted in 3.09 additional QALYs and an increase in lifetime costs of $936,430 per 1000 women, yielding an incremental cost-effectiveness ratio of $303,279 per QALY. In 98% of simulations, AI was not cost-effective at a $100,000/QALY willingness-to-pay threshold. Findings were not sensitive to changes in test characteristics likely to be observed in routine practice.

CONCLUSIONS:

AI-assisted breast cancer screening yielded modest reductions in breast cancer mortality, but at current pricing, AI is not cost-effective.

100 Deals associated with Porcine Fibrin (Guangzhou Baitejing Pharmaceutical Technology)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Postoperative Hemorrhage	Phase 2	China	Guangzhou Baitejing Pharmaceutical Technology Co., Ltd.	30 Dec 2021
Postoperative Hemorrhage	Phase 2	China	Guangzhou Zhongwei Biotechnology Co., Ltd.	30 Dec 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data